Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|February 7, 2014

Sartorius Appoints New Head of Lab Products & Services Division

Sartorius appoints Michael Melingo to head marketing, sales, and services of the Lab Products & Services Division.

Sartorius has appointed Michael Melingo to head marketing, sales, and services of the Lab Products & Services Division effective April 1, 2014. He will succeed Dominique Baly, who will retire from the company. Melingo will report to the CEO and Executive Board Chairman, Joachim Kreuzburg, and become a member of the Group Executive Committee. Previously, Melingo worked at Metrohm, a Swiss manufacturer of analytical instruments, where he was CEO of its US subsidiary. He has also worked for Baxter, Bio-Rad, Millipore, and Waters in Europe and Asia.

Source: Sartorius


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.